HER-2在新辅助化疗乳腺癌中的表达及其意义分析  

Expression of HER-2 in Breast Cancer with Neoadjuvant Chemotherapy and Clinical Signiflcance

作　　者：陈静[1] 冉立[1] 文小平[1] 

机构地区：[1]贵阳医学院附属医院肿瘤科

出　　处：《贵州医药》2006年第5期397-398,共2页Guizhou Medical Journal

摘　　要：目的检测并分析HER-2在新辅助化疗乳腺癌组织中的表达,探讨新辅助化疗患者中HER-2的临床意义。方法采用免疫组织化学法分别检测HER-2在78例新辅助化疗及22例未化疗乳腺癌组织中的表达状况。结果新辅助化疗组HER-2表达低于未化疗组(28．2％比45．4％,P <0．05);腋淋巴结转移组HER-2表达明显高于腋淋巴结阴性组(42．6％比25．6％,P<0．05)。结论 HER-2可能成为在新辅助化疗乳腺癌患者优于淋巴结状况的一个评价肿瘤生物学行为、预测治疗效果、指导综合治疗方案制定、以及判新预后的重要标志。Objective To study the clinical significance of expression of HER-2 in breast cancer with neoadjuvant chemothetapy. Methods The expression of HER-2 in 78 cases treated with neoadjuvant chemotherapy and 22 cases treated with only operation were examined by immunohistochemistry. Results The HER-2 expression in neoadjuvant chemotherapy groupwas lower than that of only operation group （P〈0. 05）. The HER-2 expression in lymph node metastatic case were higher than that without lymph node metastasis cases （P〈0. 05）. Conclusion HER-2 is a useful tumor marker in patients treated with neoadiuvant chemotherapy and can be used to evaluate tumor biological behavior, predict the sensitivity of treatment.

关 键 词：HER-2 乳腺癌 新辅助化疗 免疫组化 

分 类 号：R737.9[医药卫生—肿瘤]